Cargando…
Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience
BACKGROUND: The aim of our study was to evaluate the safety and efficacy of triple therapy using boceprevir (BOC) with pegylated interferon (pIFN)/ribavirin (RBV) in chronic hepatitis C (CHC) genotype 1 (G1) treatment-experienced patients with advanced fibrosis or compensated cirrhosis. METHODS: We...
Autores principales: | Manolakopoulos, Spilios, Kranidioti, Hariklia, Goulis, John, Vlachogiannakos, John, Elefsiniotis, John, Kouroumalis, Elias A., Koskinas, John, Kontos, George, Evangelidou, Eftychia, Doumba, Polyxeni, Sinakos, Emmanuel, Vafiadou, Ιrini, Koulentaki, Mairi, Papatheodoridis, George, Akriviadis, Evangelos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585396/ https://www.ncbi.nlm.nih.gov/pubmed/26423714 |
Ejemplares similares
-
Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis
por: Kranidioti, Hariklia, et al.
Publicado: (2018) -
Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues
por: Papadopoulos, Nikolaos, et al.
Publicado: (2018) -
Bacterial infections in patients with liver cirrhosis: clinical characteristics and the role of C-reactive protein
por: Deutsch, Melanie, et al.
Publicado: (2018) -
Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
por: Siakavellas, Spyros, et al.
Publicado: (2021) -
Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors
por: Kranidioti, Hariklia, et al.
Publicado: (2015)